Clinical Trials Browser

Approved for marketing × tafasitamab × Clear all

NCT04300803 2020-08-28

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Approved for marketing

Lymphoma, Large B-Cell, Diffuse